4D Pharma PLC

Mar 17, 2020

4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate

Jan 06, 2020

Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer

Nov 06, 2019

4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®

Oct 08, 2019

4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines

Sep 23, 2019

4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes

Jul 25, 2019

4D pharma plc: Oncology Programmes Update

Jul 08, 2019

4D pharma plc Commences Phase I/II Asthma Trial

Jun 03, 2019

4D Presents MRx0518 Combination Study at ASCO 2019, Chicago, USA

May 16, 2019

4D Presents Phase Ib Clinical Data on Thetanix®

May 13, 2019

4D Announces Participation in Neuro4D Conference, Frankfurt, Germany

Apr 29, 2019

4D Pharma Clinical Update - MRx0518 Oncology Programmes

Jan 29, 2019

4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

Jan 08, 2019

4D pharma plc: Appointment of Independent Non-Executive Directors

Jan 07, 2019

4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

Jun 27, 2018

4D Presents at IHMC 2018

Jun 07, 2018

4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours